RxDoctor Payments DataLook up a doctor →

Michelle Eisenberg, DO

Rheumatology · Houston, TXNPI 1740215375

Payments from drug & device makers

$1,794,950in general payments, 2019–2025

Across 1,399 payments — averaging $1283.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$693K
  • Amgen$462K
  • GSK$264K
  • Sanofi US Services Inc.$162K
  • AstraZeneca$133K
  • UCB SA$45K
  • plus $36K from 37 others

What the payments were for

  • Consulting fees$4,3958%
  • Speaking & faculty fees$17,81934%
  • Travel & lodging$6,51612%
  • Food & beverage$24,13646%
  • Education$1560%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,794,950 in reported general payments places this provider in the 95th percentile of 512 rheumatology providers in Texas.

See all rheumatology providers in Texas

Medicare billing

Part B allowed, 2024
$272,484
Medicare patients
120
Services billed
16,642

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab45$313,781
BenlystaBelimumab41$235,265
ProliaDenosumab124$216,778
Taltz AutoinjectorIxekizumab22$178,742
Orencia ClickjectAbatacept29$160,901
TremfyaGuselkumab11$152,115
Enbrel SureclickEtanercept19$141,326
Cosentyx Sensoready (2 Pens)Secukinumab16$141,173
Enbrel MiniEtanercept15$113,379
RemicadeInfliximab13$110,333
RinvoqUpadacitinib15$96,624
KevzaraSarilumab17$73,138
Xeljanz XrTofacitinib Citrate12$65,650
RasuvoMethotrexate/Pf22$14,044
Hydroxychloroquine Sulfate396$8,339

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonTremfya, Remicade$1,905$262,44924 claims
GSKBenlysta$264,013$235,26541 claims
AmgenProlia$461,949$216,778124 claims
AbbVieRinvoq$5,470$96,62415 claims
SanofiKevzara$413$73,13817 claims
Medexus Pharma, Inc.Rasuvo$33$14,04422 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 512 rheumatology providers in Texas.

Other rheumatology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →